Ignite Creation Date:
2024-05-05 @ 9:02 PM
Last Modification Date:
2024-10-26 @ 9:59 AM
Study NCT ID:
NCT00808002
Status:
COMPLETED
Last Update Posted:
2020-01-31
First Post:
2008-12-12
Brief Title:
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus TenofovirEmtricitabine
Sponsor:
Germans Trias i Pujol Hospital
Organization:
Germans Trias i Pujol Hospital
Study Overview
Official Title:
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus TenofovirEmtricitabine
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofoviremtricitabine could accelerate the decay of the HIV-1 reservoir in latently infected cells established early in HIV-1 infection
This could provide further insight into this area decrease the size of latent reservoir and translate into clinical benefits for patients
This could provide further insight into this area decrease the size of latent reservoir and translate into clinical benefits for patients
Detailed Description:
A reservoir of latently infected cells established early in infection may be involved in the maintenance of viral persistence despite continuous highly active antiretroviral therapy HAART This is likely to represent the major barrier to virus eradication in patients on successful combination antiretroviral therapy
The majority of the viruses in the latent reservoir use CCR5 receptor during entry
More recently clear evidences for decay of this HIV-1 reservoir in patients who initiated antiretroviral therapy early in infection have been demonstrated The treatment of acute infection may set the stage for subsequent attempts at eradication To achieve this more potent antiretroviral therapy andor more potent antilatency therapies may be needed
In contrast to previous antiretroviral drugs maraviroc does not need to cross the cell membrane nor does not require intracellular processing in order to exert its activity In addition there is no cross-resistance between entry inhibitors and agents that act on intracellular targets
Maraviroc has demonstrated potent antiviral activity against all CCR5-tropic HIV-1 viruses tested Maraviroc could thus fulfil the requirements for an optimal candidate for treatment intensification in HIV-1 infected patients with a recent HIV-1 infection
The majority of the viruses in the latent reservoir use CCR5 receptor during entry
More recently clear evidences for decay of this HIV-1 reservoir in patients who initiated antiretroviral therapy early in infection have been demonstrated The treatment of acute infection may set the stage for subsequent attempts at eradication To achieve this more potent antiretroviral therapy andor more potent antilatency therapies may be needed
In contrast to previous antiretroviral drugs maraviroc does not need to cross the cell membrane nor does not require intracellular processing in order to exert its activity In addition there is no cross-resistance between entry inhibitors and agents that act on intracellular targets
Maraviroc has demonstrated potent antiviral activity against all CCR5-tropic HIV-1 viruses tested Maraviroc could thus fulfil the requirements for an optimal candidate for treatment intensification in HIV-1 infected patients with a recent HIV-1 infection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None